By Christian Moess Laursen

GSK said it bought biopharmaceutical company Aiolos Bio for an upfront consideration of $1.0 billion and the potential for an additional $400 million, the latest in a string of pharmaceutical majors buying fast-growing biotechs to restock their pipelines.

The British pharmaceutical giant said Tuesday that the deal to buy San Francisco and London-based Aiolos Bio, which focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the treatment of adult patients with certain respiratory and inflammatory conditions.

The portfolio addition "could expand the reach of our current respiratory biologics portfolio, to the 40% of severe asthma patients with low type 2 inflammation where treatment options are still needed," Chief Scientific Officer Tony Wood said.

The additional payment of up to $400 million is dependent on certain regulatory milestones being met, it said.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

January 09, 2024 02:49 ET (07:49 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 GSK 차트를 더 보려면 여기를 클릭.
GSK (NYSE:GSK)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 GSK 차트를 더 보려면 여기를 클릭.